Celldex Therapeutics
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline ...
Latest News
7 days ago · marketbeat.com
Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 ResultsCelldex Therapeutics NASDAQ: CLDX plans to submit a biologics license application for barzolvolimab in 2027, using full 52-week data from its Phase 3 studies in chronic spontaneous urticaria, executives said at Guggenheim's 3rd Annual Healthcare Innovation Conference.
2 months ago · seekingalpha.com
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria TranscriptCelldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript
2 months ago · benzinga.com
Celldex Prepares For 2027 FDA Submission for Chronic Skin DiseaseCelldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (CSU) who experience inadequate symptom control using H1-antihistamines, including those who are advanced therapy experienced or refractory.
2 months ago · zacks.com
4 Biotech Stocks With Key Clinical Readouts Expected This FallKOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
2 months ago · reuters.com
Celldex's skin disease drug meets goals in two late-stage trialsCelldex Therapeutics said on Tuesday its experimental drug for a skin disease met the main and secondary goals of two late-stage trials.
2 months ago · globenewswire.com
Celldex to Present at Upcoming Investor ConferenceHAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.
3 months ago · zacks.com
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue EstimatesCelldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago.
4 months ago · zacks.com
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
4 months ago · seekingalpha.com
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation TranscriptCelldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript
4 months ago · benzinga.com
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis StudyCelldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday said it is ending its Phase 2 clinical trial evaluating barzolvolimab for prurigo nodularis, a chronic condition characterized by intensely itchy skin nodules.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CLDX